Pharma Manufacturers Mobilize Against 340B Discounts At Contract Pharmacies
AstraZeneca, Merck & Co., Sanofi and Novartis join Eli Lilly in taking action. But providers in the US federal discount program are pushing back.
You may also be interested in...
Manufacturer restrictions on discounts to contract pharmacies may have depressed sales for 340B-discounted diabetes drugs in 2021. But sales in other categories, including oncology, immunology and arthritis drugs, were up by 20% to 40%.
Biden Administration officials pledge ongoing efforts to thwart manufacturer restrictions on 340B drug discounts, but at the same time urge hospitals to be more transparent about how they use the savings.
Federal district court denies HHS request to dismiss AstraZeneca’s lawsuit, but also suggests Congress needs to clarify the contract pharmacy issue.